Bellus Health receives U.S. patent for BLU-5937

Alpha Stox April 24, 2017 Comments Off
Bellus Health receives U.S. patent for BLU-5937

Mr. Roberto Bellini reports

BELLUS HEALTH ANNOUNCES GRANT OF NEW U.S. PATENT COVERING LEAD COMPOUND FOR CHRONIC COUGH

The U.S. Patent and Trademark Office has issued U.S. patent No. 9,598,409, which grants claims covering the composition of matter of Bellus Health Inc.’s lead drug candidate, BLU-5937, and related imidazopyridine compounds, in addition to pharmaceutical compositions comprising BLU-5937 and uses thereof. The patent has an expiration date of 2034, excluding any potential patent term extension. Patent applications with similarly broad claims are currently pending in Europe, Japan, China and other industrialized nations.

“This U.S. patent affords broad and comprehensive composition of matter protection for our lead drug candidate, BLU-5937, in the most important pharmaceutical market in the world,” said Roberto Bellini, President and CEO of Bellus Health. “We expect the intellectual property estate for BLU-5937 to continue expanding and provide robust worldwide patent protection.”

About BLU-5937

BLU-5937 is an orally administered small molecule being developed for the treatment of chronic cough. BLU-5937 is a potent and selective antagonist of P2X3 receptors located on airway sensory neurons. In chronic cough, the P2X3 receptor is involved in hypersensitization of these neurons, leading to an increased urge to cough and a decreased threshold for cough reflex activation. The P2X3 receptor is a clinically-validated target for the treatment of chronic cough and the potent antitussive effect of BLU-5937 has been demonstrated in preclinical cough models.

About Chronic Cough

Chronic cough is a cough that lasts for more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. It is estimated that, in the United States alone, more than 27 million patients suffer from chronic cough. While an underlying etiology such as gastro-oesophageal reflux, asthma, or allergic rhinitis may contribute to cough in some of these patients, an underlying condition cannot be identified in 10%-40% of chronic cough patients (unexplained chronic cough). A portion of patients with an underlying condition as well as the large majority of unexplained chronic cough patients are not well controlled by current therapies.

About Bellus Health

Bellus Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

We seek Safe Harbor.

Comments are closed.

Newsletterpopup_top_1

Your Name (required)

Your Email (required)

captcha

Newsletterpopup_bottom_1